Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

V501 Phase II Efficacy Study in Women Aged 18 to 26

Trial Profile

V501 Phase II Efficacy Study in Women Aged 18 to 26

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Jun 2010 Actual patient number (1021) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top